Cornell Study Shows Targeted Sequencing Can ID Mutations in Advanced Prostate Cancer FFPE Samples | GenomeWeb

Collaborating with Foundation Medicine, researchers from Weill Cornell Medical College have demonstrated that targeted sequencing can identify potentially actionable mutations in formalin-fixed paraffin-embedded samples from advanced prostate cancers.

The group published in the Journal of the European Association of Urology this month results of a small study that sequenced samples from 45 patients. Sequencing the samples to an average depth of 900x yielded a number of potentially targetable mutations, including a novel rearrangement involving BRAF.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.